Innocan Pharma INNPF
OTC INNPF
$1.29 +0.00 (+0.00%)
At close: Nov 12, 2026 · 4:00 PM EST

Innocan Pharma (INNPF) Non Operating Interest Expenses (2024 - 2025)

Updated

Innocan Pharma (INNPF) reported Non Operating Interest Expenses of $42,000 for the quarter ended Dec 31, 2025, compared with -$147,000 a year earlier.

Analysis

Innocan Pharma (INNPF) Non Operating Interest Expenses (2024 - 2025) Analysis & Trends

For the year ended Dec 31, 2025, Innocan Pharma posted Non Operating Interest Expenses of $3,000, down 93.9% from the prior year.

  • By year, Non Operating Interest Expenses came in at $49,000 in the year ended Dec 31, 2024 and $4,000 in the year ended Dec 31, 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn -
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn 217.00 Mn
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn -
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn -
5 Novartis Ag 306.35 Bn 279.93 Bn - -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn -477.00 Mn
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn 653.00 Mn
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn 269.00 Mn
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn -
10 Innocan Pharma 5.78 Mn 1.73 Mn 4.43 Mn 42,000.00
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 42,000.00
Sep 30, 2025 -115,000.00
Dec 31, 2024 -147,000.00
Sep 30, 2024 -9,000.00
API Access

Innocan Pharma Non Operating Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-interest-expenses&ticker=INNPF&period=max&api_key=YOUR_API_KEY